Skip to main content
42°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
RenovoRx, Inc. - Common Stock
(NQ:
RNXT
)
1.000
+0.040 (+4.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RenovoRx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
April 01, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
March 28, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
March 26, 2025
From
RenovoRx, Inc.
Via
Business Wire
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024
August 13, 2024
RNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
March 20, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
March 19, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
February 26, 2025
From
RenovoRx, Inc.
Via
Business Wire
RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024
May 13, 2024
RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
February 13, 2025
From
RenovoRx, Inc
Via
Business Wire
BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering
February 12, 2025
Via
Investor Brand Network
Exposures
Product Safety
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
February 11, 2025
From
RenovoRx, Inc.
Via
Business Wire
What's going on in today's pre-market session
February 07, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via
Chartmill
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
February 06, 2025
From
RenovoRx, Inc.
Via
Business Wire
These stocks are moving in today's after hours session
February 06, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
RenovoRx Announces Proposed Public Offering
February 06, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
January 27, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
January 08, 2025
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
December 30, 2024
From
RenovoRx, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 02, 2024
Via
Benzinga
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
September 12, 2024
Via
Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
June 12, 2024
Via
Benzinga
RenovoRx CEO Issues Update Letter to Shareholders
May 30, 2024
From
RenovoRx, Inc.
Via
Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
May 21, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
May 14, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
May 02, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
April 18, 2024
From
RenovoRx , Inc.
Via
Business Wire
RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
April 16, 2024
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026
April 15, 2024
From
RenovoRx, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 09, 2024
Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.